<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89073">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01956552</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2009-05</org_study_id>
    <nct_id>NCT01956552</nct_id>
  </id_info>
  <brief_title>Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)</brief_title>
  <official_title>Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to compare the phenotype and genotype of the primary tumor with
      those of its metastases in order to optimize the treatment of metastatic disease, in
      patients presenting with first metastatic progression of breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment</study_design>
  <primary_outcome>
    <measure>To assess the phenotype ant genotype discrepancies regarding hormonal receptor, FISH status and proliferation between the primary tumor and the first metastatic progression.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biopsy or cytopuncture</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible to participate in the study, patients must fulfill all of the following
        criteria:

        Female patients. Age ≥ 18 years. ECOG performance status ≤ 2. Metastatic breast carcinoma,
        either at diagnosis or at first metastatic relapse.

        Available FFPE +/- frozen primary tumor samples. Evaluable metastatic disease. Metastatic
        disease outside any previous radiotherapy field (e.g. sub-clavicular or internal mammary
        lymph nodes).

        Metastatic disease accessible to either percutaneous or surgical sampling. Signed written
        informed consent (approved by an Independent Ethics Committee and obtained prior to any
        study-specific screening procedure).

        Social and psychological welfare in concordance with compliance to the study.

        Exclusion Criteria:

        To be eligible to participate in the study, patients must fulfill none of the following
        criteria:

        Bilateral or multifocal breast cancer. Isolated local or contralateral relapse.

        Solitary bone and/or brain metastatic disease unless :

        Metastatic sites eligible for a therapeutic surgery. Metastatic sites sampled for
        diagnosis purpose. Past or current history of malignant neoplasms, except for curatively
        treated basal and squamous cell carcinoma of the skin. Carcinoma in situ of the cervix.
        Any coagulopathy contraindicating tumor biopsy. Presence of a contraindication to general
        anesthesia, if required.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SIGAL BRIGITTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSTITUT DE CANCEROLOGIE DE L'OUEST René Gauducheau</name>
      <address>
        <city>Nantes Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie HOPITAL RENE HUGUENIN</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Tumor biopsy</keyword>
  <keyword>Phenotype and genotype characterization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
